<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Vaccine development has benefited from the early release of the complete genome sequence of SARS-CoV-2. As of 3 September 2020, according to the WHO, 33 vaccine candidates are at different stages of clinical development, six of which are at phase III clinical trials 
 <xref rid="b0570" ref-type="bibr">[114]</xref>. On 22 July 2020, China approved the use of two inactivated COVID-19 vaccines developed by Sinovac Biotech Co. Ltd. 
 <xref rid="b0575" ref-type="bibr">[115]</xref>. Another adenovirus vector-based SARS-CoV-2 vaccine was approved by the administrative office of Russia on 10 August 2020. U.S. authorities have recently announced the pending approval of a vaccine by the end of this year.
</p>
